ImmunityBio falls as FDA seeks more information on bid for wider bladder cancer use

Shares of drug developer ImmunityBio IBRX.O fall 4.35% to $5.28 premarket

Co says it is preparing to resubmit its application seeking U.S. approval for use of bladder cancer drug Anktiva in a broader group of patients, following new guidance from U.S. FDA

Co says FDA asked for more information but no new trials; plans resubmission within 30 days

Long-term data showed nearly all patients on Anktiva along with BCG survived ≥3 years and over 80% kept their bladder, avoiding surgery - IBRX

BCG is a decades-old bladder-cancer treatment made from a weakened bacterium that helps the immune system attack cancer cells

Co's  Anktiva is already cleared in U.S., UK, Saudi Arabia and conditionally in EU for related uses - IBRX

As of last close, stock down ~23% over the past year